Meitav Investment House Ltd. Sells 184,043 Shares of Moderna, Inc. (NASDAQ:MRNA)

Meitav Investment House Ltd. decreased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 81.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 42,860 shares of the company’s stock after selling 184,043 shares during the period. Meitav Investment House Ltd.’s holdings in Moderna were worth $1,782,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Arkadios Wealth Advisors raised its position in Moderna by 2.2% in the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC lifted its position in Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares in the last quarter. Stephens Inc. AR lifted its position in Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after buying an additional 245 shares in the last quarter. Allworth Financial LP increased its position in Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after acquiring an additional 281 shares in the last quarter. Finally, Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Price Performance

MRNA opened at $35.90 on Thursday. The company has a market capitalization of $13.82 billion, a price-to-earnings ratio of -3.87 and a beta of 1.59. The business’s 50-day moving average price is $38.35 and its two-hundred day moving average price is $53.34. Moderna, Inc. has a 1 year low of $29.25 and a 1 year high of $170.47.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MRNA. Royal Bank of Canada restated a “sector perform” rating and issued a $40.00 price objective on shares of Moderna in a research report on Tuesday. Evercore ISI cut their price target on Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research note on Monday, January 27th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Leerink Partners lowered their price target on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research report on Thursday, January 16th. Finally, Wolfe Research started coverage on shares of Moderna in a report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $60.63.

Insider Activity at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.20% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.